Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
TScan lays off 30% of workforce, halts solid tumor TCR trial
TScan is laying off 30% of its workforce as the T-cell receptor therapy biotech focuses on patients with blood cancers.
James Waldron
Nov 3, 2025 8:25am
Nanobiotix finds new way to source cash from J&J-partnered drug
Oct 31, 2025 6:05am
Sensei drops sole clinical-stage cancer drug, plans layoffs
Oct 30, 2025 9:52am
AbbVie halts development of Dragonfly cancer asset in midflight
Oct 29, 2025 1:47pm
Roche axes 4 Chugai solid tumor assets in early-phase clear-out
Oct 23, 2025 4:53am
Takeda strikes Innovent pact worth up to $11.4B
Oct 22, 2025 9:15am
